Drugs / Cytotoxic T Lymphocytes
Cytotoxic T Lymphocytes
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04765449 | Sep 2021 → Jul 2022 | COVID-19 | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 1 | NCT01535885 | Feb 2012 → Oct 2019 | Epstein-Barr virus infection, adenoviridae infectious disease, cytomegalovirus infection | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03266653 | Jul 2020 → Dec 2026 expected | Epstein-Barr virus infection, immunodeficiency disease | New York Medical College | Recruiting | No outcome recorded |
| Phase 2 | NCT03266627 | Nov 2018 → Dec 2026 expected | adenoviridae infectious disease, inborn error of immunity | New York Medical College | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07225972 | Dec 2026 → Dec 2031 expected | adenoviridae infectious disease, cytomegalovirus infection | New York Medical College | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2024-10-15 | Tevogen Bio Inc | Results Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company’s Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use tevogen.com ↗
Patients in the treatment group had symptom improvement and resolution more consistently, and in many cases, faster, than those in the observation group. |
| 2024-06-25 | Tevogen Bio Inc | Results Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances tevogen.com ↗
Tevogen Bio Holdings (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, reports publication of its phase I clinical trial data of TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy by the journal Blood Advances . |
| 2024-06-06 | Tevogen Bio Inc | Results Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2 tevogen.com ↗
Continuing surveillance by Tevogen Bio of SARS-CoV-2 variants, show that 95% of these CTLs remain active against FLiRT variants, including KP.2, the current dominant strain. |
| 2024-03-20 | Tevogen Bio Inc | Results Tevogen Bio Reports Its Investigational SARS-CoV-2 Specific T Cell Therapy, TVGN-489, Retains Activity Against the Dominant JN.1 Variant tevogen.com ↗
Continuing surveillance by Tevogen Bio of SARS-CoV-2 variants, including the currently dominant JN.1 strain and newer JN.1 strains, show that 96% of these CTLs remain active against the current circulating variants. |
All press releases naming this drug 5 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cytotoxic t-lymphocytes | “Family donor-derived viral specific cytotoxic T lymphocytes (CTLs) plus standard of care (SOC) vs SOC alone” NCT07225972 ↗ |
| Known as | CTL | “This protocol is a phase I study. Patients may be eligible for an infusion of Multi-virus Cytotoxic T Lymphocytes (CTL) if they received a T-cell depleted (TCD) transplant from...” NCT01535885 ↗ |
| Known as | CTLs | “Family donor-derived viral specific cytotoxic T lymphocytes (CTLs) plus standard of care (SOC) vs SOC alone” NCT07225972 ↗ |
| Known as | Multi-virus Cytotoxic T Lymphocytes (CTL) | “This protocol is a phase I study. Patients may be eligible for an infusion of Multi-virus Cytotoxic T Lymphocytes (CTL) if they received a T-cell depleted (TCD) transplant from...” NCT01535885 ↗ |
| Action | Deplete | “Cytotoxic T lymphocytes (CTLs) destroy virally infected cells and are critical for the elimination of viral infections such as those caused by the severe acute respiratory...” PMID 38885482 ↗ Aug 2024 |
| Modality | Cell therapy | “adoptive transfer of Cytotoxic T Lymphocytes (CTL)” NCT01535885 ↗ |
| Route | Intravenous | “will be administered intravenously” NCT03266627 ↗ |